Goldman Sachs
TCRT icon

Goldman Sachs’s Alaunos Therapeutics TCRT Stock Holding History

Goldman Sachs’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-68
Closed -$718 – 5868
2023
Q4 		$718 Sell
68
-286
-81% -$3.44K ﹤0.01% 5584
2023
Q3 		$7K Sell
354
-5
-1% -$215 ﹤0.01% 5422
2023
Q2 		$27.5K Sell
359
-22
-6% -$1.78K ﹤0.01% 5515
2023
Q1 		$36K Sell
381
-773
-67% -$73.6K ﹤0.01% 5596
2022
Q4 		$112K Sell
1,154
-627
-35% -$90.9K ﹤0.01% 5454
2022
Q3 		$460K Buy
1,781
+520
+41% +$151K ﹤0.01% 5036
2022
Q2 		$0 Sell
1,261
-29,116
-96% -$2.78M ﹤0.01% 6712
2022
Q1 		$2.97M Buy
30,377
+27,101
+827% +$3.48M ﹤0.01% 3872
2021
Q4 		$536K Buy
3,276
+330
+11% +$72.5K ﹤0.01% 5324
2021
Q3 		$804K Buy
2,946
+408
+16% +$125K ﹤0.01% 4911
2021
Q2 		$1M Buy
2,538
+204
+9% +$95.2K ﹤0.01% 4752
2021
Q1 		$1.26M Sell
2,334
-404
-15% -$252K ﹤0.01% 4433
2020
Q4 		$1.03M Sell
2,738
-10,504
-79% -$4.18M ﹤0.01% 4178
2020
Q3 		$5M Buy
13,242
+627
+5% +$277K ﹤0.01% 2903
2020
Q2 		$6.21M Buy
12,615
+10,539
+508% +$4.7M ﹤0.01% 2637
2020
Q1 		$763K Buy
2,076
+219
+12% +$113K ﹤0.01% 3939
2019
Q4 		$1.31M Sell
1,857
-356
-16% -$245K ﹤0.01% 3944
2019
Q3 		$1.42M Buy
2,213
+1,123
+103% +$891K ﹤0.01% 3785
2019
Q2 		$953K Buy
1,090
+208
+24% +$143K ﹤0.01% 4030
2019
Q1 		$510K Buy
882
+131
+17% +$54.8K ﹤0.01% 4413
2018
Q4 		$211K Sell
751
-62
-8% -$24.5K ﹤0.01% 4800
2018
Q3 		$390K Sell
813
-182
-18% -$78K ﹤0.01% 4554
2018
Q2 		$450K Buy
995
+559
+128% +$354K ﹤0.01% 4571
2018
Q1 		$256K Sell
436
-533
-55% -$332K ﹤0.01% 4869
2017
Q4 		$601K Sell
969
-98
-9% -$70.4K ﹤0.01% 4688
2017
Q3 		$982K Buy
1,067
+894
+517% +$794K ﹤0.01% 4592
2017
Q2 		$162K Sell
173
-569
-77% -$558K ﹤0.01% 5908
2017
Q1 		$706K Sell
742
-737
-50% -$686K ﹤0.01% 4702
2016
Q4 		$1.19M Sell
1,479
-295
-17% -$266K ﹤0.01% 4298
2016
Q3 		$1.5M Buy
1,774
+839
+90% +$674K ﹤0.01% 4056
2016
Q2 		$770K Sell
935
-193
-17% -$210K ﹤0.01% 4433
2016
Q1 		$1.25M Sell
1,128
-450
-29% -$461K ﹤0.01% 3888
2015
Q4 		$1.97M Buy
1,578
+484
+44% +$801K ﹤0.01% 3644
2015
Q3 		$1.48M Sell
1,094
-1,222
-53% -$2.02M ﹤0.01% 4094
2015
Q2 		$4.17M Buy
2,316
+839
+57% +$1.3M ﹤0.01% 3124
2015
Q1 		$2.38M Buy
1,477
+220
+18% +$326K ﹤0.01% 3607
2014
Q4 		$956K Buy
1,257
+443
+54% +$235K ﹤0.01% 4622
2014
Q3 		$322K Buy
814
+669
+461% +$323K ﹤0.01% 5693
2014
Q2 		$88K Sell
145
-74
-34% -$41.2K ﹤0.01% 6606
2014
Q1 		$150K Sell
219
-420
-66% -$281K ﹤0.01% 6236
2013
Q4 		$416K Sell
639
-248
-28% -$148K ﹤0.01% 5438
2013
Q3 		$524K Sell
887
-345
-28% -$155K ﹤0.01% 5130
2013
Q2 		$390K Buy
+1,232
New +$342K ﹤0.01% 5139

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return

Goldman Sachs's TCRT Position: Q1 2024 in Review

Goldman Sachs sold out of Alaunos Therapeutics (TCRT) in Q1 2024, closing a stake of 68 shares — an estimated $718 sold.

Goldman Sachs first reported a position in TCRT in Q2 2013 and held it in 43 quarters. The position peaked at $6.21M in Q2 2020. 45 funds tracked by Wall St. Rank hold TCRT as of Q1 2024.

  • Goldman Sachs reported no remaining Alaunos Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Goldman Sachs sold 68 Alaunos Therapeutics shares in Q1 2024, an estimated $718.
  • Goldman Sachs first reported a position in Alaunos Therapeutics in Q2 2013 and held it in 43 quarters.
  • Goldman Sachs's Alaunos Therapeutics position peaked at $6.21M in Q2 2020.
  • 45 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2024.

Based on Goldman Sachs's 13F filing for Q1 2024, filed 15 May 2024.